Colorectal cancer is the fourth most common malignancy and the second most frequent cause of cancer-related death in the United States, with approximately 50 000 cancer-related deaths in 2009 ([@bib17]). Colorectal cancer arises through a multistep carcinogenic process in which genetic and epigenetic alterations (e.g., microsatellite instability (MSI), CpG island methylation, mutations in *KRAS*, *BRAF* and *PIK3CA*) accumulate in a sequential manner. A better understanding of molecular alterations in colorectal cancer may be of great clinical importance. *KRAS* mutational status of stage IV colorectal cancer is a predictive biomarker for anti-EGFR treatment ([@bib24]). In addition, *BRAF* mutation identifies a subgroup of patients with unfavourable prognosis ([@bib39]; [@bib46]).

AMP-activated protein kinase (AMPK; PRKA, the HUGO-approved official gene stem symbol) is a heterotrimeric serine/threonine protein kinase, which acts as a cellular sensor for energy balance status. AMP-activated protein kinase is phosphorylated by its upstream kinase STK11 (LKB1) in response to an increase in cellular AMP/ATP ratio ([@bib49]). It regulates cell proliferation and growth by inhibition of the MTOR pathway and fatty acid synthesis, and activation of the TP53-CDKN1A (p21) pathway ([Figure 1](#fig1){ref-type="fig"}) ([@bib15]). The MAPK3/1 (extracellular signal-regulated kinase (ERK)1/2) pathway is activated by extracellular and intracellular mitogenic stimuli and has crucial roles in cellular differentiation, proliferation and survival ([@bib48]). Interactions between the STK11 (LKB1)-AMPK pathway and the MAPK3/1 pathway in human cancer cells including colon cancer cells have been documented ([@bib7]; [@bib55]; [@bib22]). AMP-activated protein kinase activation is cytotoxic to various cancer cell types, and inhibits tumour growth ([@bib4]; [@bib54]), supporting AMPK as a tumour suppressor and a potential target for cancer therapy and chemoprevention ([@bib9]). Thus, better understanding of the mechanism and consequence of AMPK activation in human cancer is increasingly important. To our best knowledge, no previous study has examined AMPK status and patient prognosis in human colorectal cancer. Given potential roles of AMPK as a regulator of cellular metabolism and a tumour suppressor related to cellular signaling pathways (e.g., the MAPK3/1 pathway), we hypothesised that AMPK might interact with MAPK3/1 to modify tumour behaviour.

To test this hypothesis, we utilised a database of 718 stage I--IV colorectal cancers in two prospective cohort studies, and examined the prognostic role of phosphorylated-AMPK expression and modifying effect of MAPK3/1. As a result of our database with other tumoral variables including FASN, TP53, *KRAS*, *BRAF* and *PIK3CA* mutations, MSI, the CpG island methylator phenotype (CIMP) and LINE-1 methylation, we could examine the relationship between AMPK status and other molecular features, as well as interactive prognostic effect of AMPK and other molecular events.

Materials and methods
=====================

Study group
-----------

We utilised the databases of two independent, prospective cohort studies; the Nurses\' Health Study (*N*=121 701 women followed since 1976), and the Health Professionals Follow-Up Study (*N*=51 529 men followed since 1986) ([@bib5]). A subset of the cohort participants developed colorectal cancers during prospective follow-up. We collected paraffin-embedded tissue blocks from hospitals where patients underwent tumour resections. We excluded cases for which preoperative treatment was administered. Tissue sections from all colorectal cancer cases were reviewed by a pathologist (SO) unaware of other data. The tumour grade was categorised as low *vs* high (⩾50 *vs* \<50% gland formation). The type of tumour border (expansile or infiltrative) was categorised as previously published criteria ([@bib41]). On the basis of the availability of adequate tissue specimens and follow-up data, a total of 718 colorectal cancers (diagnosed up to 2004) were included. Patients were observed until death or 30 June 2008, whichever came first. Among our cohort studies, there was no significant difference in demographic features between cases with tissue available and those without available tissue ([@bib5]). This current analysis represents a new analysis of p-AMPK and p-MAPK3/1 on the existing colorectal cancer database that has been previously characterised for CIMP, MSI, *KRAS, BRAF, PIK3CA*, LINE-1 methylation and clinical outcome ([@bib35], [@bib38], [@bib39]). However, in any of our previous studies, we have neither examined AMPK or MAPK3/1 expression. Informed consent was obtained from all study subjects. Tissue collection and analyses were approved by the Harvard School of Public Health and Brigham and Women\'s Hospital Institutional Review Boards.

Sequencing of *KRAS*, *BRAF* and *PIK3CA* and MSI analysis
----------------------------------------------------------

DNA was extracted from tumour tissue, and PCR and pyrosequencing targeted for *KRAS* (codons 12 and 13) ([@bib34]), *BRAF* (codon 600) ([@bib36]) and *PIK3CA* (exons 9 and 20) were performed ([@bib28]). The status of MSI was determined by analysing variability in the length of the microsatellite markers from tumour DNA compared with normal DNA. We used D2S123, D5S346, D17S250, BAT25, BAT26 BAT40, D18S55, D18S56, D18S67 and D18S487 ([@bib30]). Microsatellite instability-high was defined as the presence of instability in ⩾30% of the markers, and MSI-low/microsatellite stability (MSS) as instability in 0--29% of the markers according to the Bethesda guideline ([@bib2]).

Methylation analyses for CpG islands and LINE-1
-----------------------------------------------

Using validated bisulphite DNA treatment and real-time PCR (MethyLight), we quantified DNA methylation in eight CIMP-specific promoters (*CACNA1G, CDKN2A* (p16), *CRABP1, IGF2, MLH1, NEUROG1, RUNX3* and *SOCS1*) ([@bib52]; [@bib32], [@bib35]). The CIMP-high was defined as the presence of ⩾6 out of 8 methylated promoters, CIMP-low/0 as 0 out of 8--5 out of 8 methylated promoters, based on a distribution of tumours and *BRAF* and *KRAS* mutation frequencies ([@bib35]). Concordance between our eight-marker panel and the Weisenberger panel ([@bib52]) was very high (99%, *κ*=0.94, *P*\<0.0001) ([@bib27]). In order to accurately quantify relatively high methylation levels in LINE-1, we utilised pyrosequencing ([@bib37]; [@bib16]).

Immunohistochemistry
--------------------

Tissue microarrays were constructed as previously described ([@bib31]). Methods of immunohistochemistry were previously described for TP53 and FASN (fatty acid synthase) ([@bib30], [@bib40]). For AMP-activated protein kinase (AMPK, PRKA), we evaluated PRKAA (AMPK*α*) Thr172 phosphorylation status ([Figure 2](#fig2){ref-type="fig"}). Deparaffinised tissue sections in Antigen Retrieval Citra Solution (Biogenex Laboratories, San Ramon, CA, USA) were treated with microwave in a pressure cooker (25 min). Tissue sections were incubated with 5% normal goat serum (Vector Laboratories, Burlingame, CA, USA) in phosphate-buffered saline (30 min). Primary antibody against p-AMPK (rabbit monoclonal anti-phospho-AMPK*α* (Thr172) (40H9), 1 : 100 dilution; Cell Signaling Technology, Boston, MA, USA) was applied ([@bib18]; [@bib6]; [@bib12]; [@bib51]; [@bib55]), and the slides were maintained at 4 °C for overnight, followed by rabbit secondary antibody (Vector Laboratories) (60 min), an avidin--biotin complex conjugate (Vector Laboratories) (60 min), diaminobenzidine (5 min) and methyl-green counterstain. Cytoplasmic p-AMPK expression was recorded as no expression, weak expression or moderate/strong expression with the percentage of positive tumour cells. The CIMP status reflects global epigenomic aberrations in tumour cells ([@bib33]) and may influence energy sensing status of cancer cells. Indeed, epidemiological studies has suggested a potential link between CIMP and energy metabolism in colorectal cancer; high intake of high-fat dairy products is associated with CIMP-high rectal cancers ([@bib50]) and exposure to a period of severe transient energy restriction during adolescence is inversely associated with the risk of having a CIMP-high tumour later in life ([@bib13]). In addition, the relationship between CIMP and a molecular alteration related to energy metabolism (e.g., SIRT1) has been reported ([@bib29]). Thus, we explored the use of CIMP status to determine a cutoff for p-AMPK positivity; there was no alternative biologically based method in our cohort studies. First, we categorised tumours according to intensity of p-AMPK and the fraction of p-AMPK-expressing cells. In our initial exploratory analysis, we randomly selected 358 tumours as a training set, leaving the remaining 360 tumours as a validation set. Using the training set, the frequency of CIMP-high in each category was: 25% (29 out of 117) in tumours with no expression; 21% (11 out of 53) in tumours with weak expression in 1--19% of tumour cells; 12% (14 out of 117) in tumours with weak expression in 20--100% of cells; 7.8% (5 out of 64) in tumours with moderate or strong expression. Thus, p-AMPK positivity was defined as the presence of weak cytoplasmic expression in ⩾20% of tumour cells or moderate/strong expression in any fraction of tumour cells. In the remaining validation set, p-AMPK expression defined by the training set was inversely associated with CIMP-high (odds ratio (OR) 0.45; 95% confidence interval (CI): 0.25--0.83; *P*=0.0094), validating the cutoff although it might not be the most biologically reasonable cutoff. In addition, to evaluate whether p-AMPK expressions in tumour centre and invasive front were different, we stained 20 whole tissue sections for p-AMPK and recorded p-AMPK expression status of both tumour centre and tumour invasive front.

For phosphorylated-MAPK3/1 (p-MAPK3/1), the same protocol with p-AMPK was used except for primary antibody (rabbit monoclonal anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Thr204) (20G11), 1 : 100 dilution; Cell Signaling Technology). Nuclear p-MAPK3/1 expression was recorded as no, weak, moderate or strong expression with the percentage of positive tumour cells. Considering that MAPK3/1 is downstream of the RAF pathway, we used *BRAF* mutation frequency to determine a cutoff for p-MAPK3/1 positivity. First, we categorised tumours according to the intensity of p-MAPK3/1 expression. Using the training set, the frequency of *BRAF* mutation in each category was: 17% (35 out of 206) in tumours with no expression; 8.5% (6 out of 71) in tumours with weak expression; 7.0% (4 out of 57) in tumours with moderate or strong expression. Thus, p-MAPK3/1 positivity was defined as weak/moderate/strong expression. In the remaining validation set, p-MAPK3/1 expression defined by the training set was inversely associated with *BRAF* mutation (OR 0.42; 95% CI: 0.20--0.90; *P*=0.023), validating the cutoff although it might not be the most biologically reasonable cutoff.

Appropriate positive and negative controls were included in each run of immunohistochemistry. Each immunohistochemical maker was interpreted by one of the investigators (p-AMPK and p-MAPK3/1 by YB; TP53 and FASN by SO) unaware of other data. For agreement studies, a random selection of 108--246 cases was examined for each marker by a second observer (by KN) unaware of other data. The concordance between the two observers (all *P*\<0.0001) was 0.82 (*κ*=0.63; *N*=137) for p-AMPK, 0.86 (*κ*=0.70; *N*=137) for p-MAPK3/1, 0.87 (*κ*=0.75; N=108) for TP53 and 0.93 (*κ*=0.57; *N*=246) for FASN, indicating good-to-substantial agreement.

Statistical analysis
--------------------

For all statistical analyses, we used SAS program (Version 9.1, SAS Institute, Cary, NC, USA). All *P-*values were two-sided, and statistical significance was set at *P*=0.05. Nonetheless, when we performed multiple hypothesis testing, a *P*-value for significance was adjusted by Bonferroni correction to *P*=0.0029 (=0.05/17). For categorical data, the *χ*^2^ test was performed. For survival analysis, Kaplan--Meier method and log-rank test was used. For analyses of colorectal cancer-specific mortality, deaths as a result of causes other than colorectal cancer were censored. To assess independent effect of p-AMPK on mortality, tumour stage (I, IIA, IIB, IIIA, IIIB, IIIC, IV, unknown) was used as a stratifying variable in Cox models using the 'strata\' option in the SAS 'proc phreg\' command to avoid residual confounding and overfitting. We constructed a multivariate, stage-stratified Cox proportional hazards model to compute a hazard ratio (HR) according to p-AMPK status, initially including sex, age at diagnosis (continuous), body mass index (BMI, \<30 *vs* ⩾30 kg m^--2^), family history of colorectal cancer in any first-degree relative (present *vs* absent), tumour location (rectum *vs* colon), tumour grade (low *vs* high), tumour border (infiltrative *vs* expansile), CIMP (high *vs* low/0), MSI (high *vs* low/MSS), LINE-1 methylation (continuous), *BRAF*, *KRAS*, *PIK3CA*, TP53 and FASN. A backward stepwise elimination with a threshold of *P*=0.20 was used to select variables in the final model. For cases with missing information in any of categorical variables (tumour location (1.2%), MSI (1.9%), *BRAF* (1.7%), *KRAS* (1.3%), *PIK3CA* (10%), TP53 (0.6%) and FASN (1.0%)), we included those cases in a majority category of a given covariate to avoid overfitting. We confirmed that excluding cases with missing information in any of the covariates did not substantially alter results (data not shown). The proportionality of hazard assumption was satisfied by evaluating time-dependent variables, which were the cross-product of the AMPK variable and survival time (*P*\>0.05). An interaction was assessed by including the cross product of p-AMPK variable and another variable of interest (without data-missing cases) in a multivariate Cox model, and the Wald test was performed. Backward stepwise elimination with a threshold of *P*=0.20 was used to select variables in the final model. A *P*-value for significance was adjusted to *P*=0.0029 by Bonferroni correction for multiple hypothesis testing.

Results
=======

AMPK expression in colorectal cancer
------------------------------------

To evaluate whether phosphorylated AMPK (p-AMPK, p-PRKA) expressions in tumour centre and invasive front were different, we stained 20 whole tissue sections for p-AMPK and recorded p-AMPK expression status of both tumour centre and tumour invasive front. In 16 of 20 sections, tumour centre and tumour invasive front showed concordant expression status, indicating that p-AMPK expressions in tumour centre and invasive front were not different in most cases. Furthermore, whole tissue section-based expression status and TMA-based expression status were concordant in 18 of 20 cases, indicating that expression status determined using TMA represented expression status of tumour as a whole in a vast majority of cases.

Among 718 colorectal cancers in the two prospective cohort studies, we detected p-AMPK in 409 tumours (57%) by immunohistochemistry. hosphorylated AMPK expression was associated with p-MAPK3/1 expression (*P*\<0.0001) and inversely with high tumour grade (*P*=0.0009), MSI-high (*P*=0.0021) and CIMP-high (*P*\<0.0001) ([Table 1](#tbl1){ref-type="table"}).

AMPK expression and prognosis in colorectal cancer
--------------------------------------------------

Among the 718 patients (with median follow-up of 129 months for censored patients), there were 306 deaths, including 194 colorectal cancer-specific deaths. In Kaplan--Meier or Cox regression analysis, p-AMPK status was not significantly associated with colorectal cancer-specific or overall survival among all eligible patients ([Figure 3A](#fig3){ref-type="fig"}, [Table 2](#tbl2){ref-type="table"}).

Modifying effect of p-MAPK3/1 expression on p-AMPK expression in survival analysis
----------------------------------------------------------------------------------

Considering experimental data on the interaction between AMPK and MAPK3/1 ([@bib7]; [@bib55]; [@bib22]), we assessed whether p-MAPK3/1 status could modify the prognostic effect of p-AMPK expression. We found a significant modifying effect of p-MAPK3/1 expression on the relation between p-AMPK expression and mortality (*P*~interaction~=0.0017 (for colorectal cancer-specific mortality) and *P*~interaction~=0.0026 (for overall mortality)). Among patients with p-MAPK3/1-positive tumour, p-AMPK expression was associated with a significant decrease in colorectal cancer-specific mortality (adjusted HR 0.42; 95% CI: 0.24--0.74), whereas p-AMPK expression was not significantly related with prognosis among patients with p-MAPK3/1-negative tumour (adjusted HR 1.22; 95% CI: 0.85--1.75; p-AMPK-positive *vs* negative) ([Table 3](#tbl3){ref-type="table"}).

In Kaplan--Meier method, the differential prognostic effect of p-AMPK expression according to p-MAPK3/1 expression status was evident ([Figure 3A](#fig3){ref-type="fig"}). hosphorylated AMPK expression was associated with longer colorectal cancer-specific survival (log-rank *P*=0.0006) among p-MAPK3/1-positive cases, whereas p-AMPK expression was not significantly associated with survival among p-MAPK3/1-negative cases (log-rank *P*=0.45).

Prognostic effect of p-MAPK3/1 expression in strata of p-AMPK status
--------------------------------------------------------------------

In Kaplan--Meier analysis, p-MAPK3/1 was not significantly associated with colorectal cancer-specific survival (log-rank *P*=0.31) ([Figure 3B](#fig3){ref-type="fig"}) or overall survival (log-rank *P*=0.68). In light of the significant interaction between p-AMPK and p-MAPK3/1 (*P*~interaction~=0.0017), we examined the prognostic effect of p-MAPK3/1 expression in strata of p-AMPK expression status. Among p-AMPK-negative cases, p-MAPK3/1 expression was significantly associated with inferior colorectal cancer-specific survival (adjusted HR 1.94; 95% CI: 1.17--3.24; p-MAPK3/1-positive *vs* negative tumours). In contrast, among p-AMPK-positive cases, p-MAPK3/1 expression was significantly associated with superior colorectal cancer-specific survival (adjusted HR 0.55; 95% CI: 0.35--0.86) ([Table 3](#tbl3){ref-type="table"}). A similar interaction was observed in overall mortality analysis (*P*~interaction~=0.0026).

Stratified analysis of p-AMPK expression and mortality
------------------------------------------------------

We examined whether the influence of p-AMPK expression on colorectal cancer-specific survival was modified by any of the other variables including sex, age, BMI, family history of colorectal cancer, tumour location, stage, tumour grade, CIMP, MSI, *BRAF*, *KRAS*, *PIK3CA*, LINE-1 methylation, TP53 and FASN. We did not observe a significant modifying effect by any of the variables (all *P*~interaction~\>0.10). Notably, there was no significant interaction between p-AMPK and mutation in *KRAS* or *BRAF* (*P*~interaction~=0.12 for *BRAF* and *P*~interaction~=0.30 for *KRAS*).

Discussion
==========

We conducted this study to examine prognostic significance of p-AMPK (phosphorylated AMP-activated protein kinase; p-PRKA) expression in a large cohort of colorectal cancers. To our best knowledge, no previous study has examined its prognostic role in human colorectal cancer. Considering a pivotal role of AMPK as a regulator of cellular metabolism and the relationship of AMPK with the MAPK3/1 (ERK1/2) pathway and other signaling pathways, we hypothesised that cellular AMPK might interact with MAPK3/1 to modify tumour behaviour. Notably, we found that the prognostic effect of p-AMPK expression differed according to p-MAPK3/1 status. hosphorylated AMPK expression was associated with superior survival among p-MAPK3/1-positive cases, but not among p-MAPK3/1-negative cases. Our results support an interaction between the AMPK and MAPK3/1 pathways in colorectal cancer cells to modify tumour behaviour.

Examining molecular changes or prognostic factors is important in cancer research ([@bib10]; [@bib11]; [@bib19]; [@bib44]; [@bib23]; [@bib45]; [@bib56]). Accumulating evidence suggests that AMPK acts as a tumour suppressor. STK11 (LKB1) has been identified as an upstream activator of AMPK ([@bib49]), and TSC2, which is a negative regulator of MTOR, is a downstream effector of AMPK ([@bib15]). Experimental studies have shown that AMPK activation inhibits cancer cell proliferation and growth ([@bib4]; [@bib54]). In a study using 354 breast cancers ([@bib12]), p-AMPK expression was not significantly associated with prognosis, but modifying effect of MAPK3/1 was not examined. To our knowledge, no previous study has examined the prognostic role of AMPK in colorectal cancer.

Considering experimental data on the link between the STK11 (LKB1)-AMPK and MAPK3/1 pathways, the modifying effect of MAPK3/1 on AMPK may not be surprising. In colon cancer cells, AMPK potentially inhibits the MAPK3/1 pathway; inhibition of AMPK by expressing a dominant-negative form potentiates MAPK3/1 activation under glucose deprivation ([@bib22]). Selenium, an essential trace element, blocks the carcinogenic agent-induced MAPK3/1 activation via AMPK ([@bib14]). AMP-activated protein kinase is rapidly activated by cisplatin and suppresses an apoptotic signal via MAPK3/1 in colon cancer cells ([@bib20]). A study using melanoma cells ([@bib55]) has shown that the MAPK3/1 pathway phosphorylates STK11 on Ser325 and Ser428 and promotes the uncoupling of AMPK from STK11, which negatively regulates AMPK. Regulation of AMPK activity by the MAPK3/1 pathway, independent of STK11 Ser428 phosphorylation, has also been reported ([@bib7]). In fibroblast cells, AMPK differentially inhibits the MAPK3/1 pathway by inhibiting RAS activation or stimulating the RAS-independent pathway in response to cellular energy status ([@bib21]). We should also consider the complex TSC2-MTOR axis-mediated linkage. AMP-activated protein kinase suppresses MTOR activity directly by phosphorylating MTOR at Thr2446 and indirectly by phosphorylating TSC2 at Thr1227 and Ser1345 and increasing the activity of TSC-complex ([@bib15]). MAPK3/1 increases MTOR activity by phosphorylating TSC2 at Ser540 and Ser664, which causes the attenuation of TSC2 ([@bib25]). Our findings may support the hypothesis that AMPK activation can make a strong impact on tumour behaviour as the 'brake\' only when MAPK3/1 is active. Additional studies are needed to confirm our findings and elucidate the exact mechanism of effect of MAPK3/1 on AMPK to modify tumour behaviour.

Our study has shown that MAPK3/1 activation has a differential effect on patient mortality according to AMPK status; p-MAPK3/1 expression is associated with good prognosis among p-AMPK-positive patients, but with poor prognosis among p-AMPK-negative patients. It remains controversial how MAPK3/1 activation affects behaviour of different cancers ([@bib26]; [@bib42]). A study on 135 colorectal cancers has shown that p-MAPK3/1 expression is associated with poor prognosis ([@bib47]). In contrast to that study (*N*=135), our study evaluated the expression status of both p-MAPK3/1 and p-AMPK in a much larger cohort of 718 colorectal cancers. In addition, we assessed the interactive effect of p-MAPK3/1 and p-AMPK expression independent of other molecular events that have been documented to be critical in colorectal carcinogenesis.

Recently, AMPK has been proposed as a potential target for cancer prevention and treatment, and various AMPK activators have been preclinically assessed ([@bib9]). Among them, metformin, a widely used anti-diabetic drug, has shown promising results ([@bib4]; [@bib54]). Metformin may have two properties of potential oncologic relevance: it has a direct, STK11-AMPK pathway-dependent growth inhibitory effect and decreases systemic insulin levels ([@bib43]). Interestingly, two observational studies have shown that diabetic patients treated with metformin experienced a lower incidence of any kind of cancer and a lower cancer-related mortality ([@bib8]; [@bib3]). Hereafter, in clinical trial of this drug, examining AMPK status in cancer tissue might be important. In this regard, our findings may have clinical implications. In addition, drugs targeting the MAPK3/1 pathway are intensively being developed and tested in clinical trials for various human cancers ([@bib1]). Although the usefulness of MAPK3/1 expression as a biomarker for sensitivity to these drugs is uncertain ([@bib53]), further understanding of the linkage between the AMPK and MAPK3/1 pathways could potentially provide useful information for refinement of therapeutic strategies.

We found significant relations of p-AMPK expression with MSI-high and CIMP-high. MSI and CIMP status reflect global genomic and epigenomic aberrations in tumour cells, and hence, are associated with various clinical, pathologic and molecular features ([@bib33]). Considering the known relationship between MSI and/or CIMP and molecular alterations related to energy metabolism ([@bib35]; [@bib29]), MSI and CIMP may influence energy sensing status of cancer cells.

There are limitations in this study. For example, data on cancer treatment were limited. Nonetheless, it is unlikely that chemotherapy use substantially differed according to AMPK status in tumour, because such data were unavailable for treatment decision making. In addition, our multivariate survival analysis finely adjusted for disease stage (I, IIA, IIB, IIIA, IIIB, IIIC, IV, unknown), on which treatment decision making was mostly based. As another limitation, beyond cause of mortality, data on cancer recurrence were unavailable in these cohort studies. Nonetheless, colorectal cancer-specific survival might be a reasonable surrogate of colorectal cancer-specific outcome. Furthermore, the cutoffs for p-AMPK and p-MAPK3/1 used in this current study need to be validated in an independent data set.

There are advantages in utilising the database of the two prospective cohort studies, the Nurses\' Health Study and the Health Professionals Follow-Up Study, to examine prognostic significance of tumour AMPK expression. Anthropometric measurements, family history, cancer staging, and other clinical, pathologic, and tumour molecular data were prospectively collected, blinded to patient outcome. Cohort participants who developed cancer were treated at hospitals throughout the United States, and thus more representative colorectal cancers in the US population than patients in one to several academic hospitals. There was no demographic difference between cases with tumour tissue analysed and those without tumour tissue analysed ([@bib5]). Finally, our rich tumour database enabled us to simultaneously assess pathologic and tumoral molecular correlates and control for confounding by a number of tumoral molecular alterations.

In summary, we have shown that AMPK activation is associated with good prognosis among MAPK3/1-activated colorectal cancer patients, while AMPK activation is not associated with prognosis among MAPK3/1-inactive cancer patients. Additional studies are necessary to confirm our observations and to elucidate exact mechanisms by which AMPK and MAPK3/1 interact and affect tumour behaviour. This possible interaction between the AMPK and MAPK3/1 pathways may have considerable implications because both pathways are potential targets for cancer treatment and prevention. In this regard, examining AMPK and MAPK3/1 status in cancer tissue may be important in future clinical trials.
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![Schematic representation of the AMPK pathway in relation to various molecules. Arrows and lines indicate the pathways potentially related with the complex interaction between AMPK and MAPK3/1. Circles indicate the tissue markers analysed in our current study.](6605846f1){#fig1}

![hosphorylated AMPK and p-MAPK3/1 expression in colorectal cancer. (**A**) Positive for p-AMPK cytoplasmic expression (arrowheads). (**B**) Negative for p-AMPK expression (white arrowheads). (**C**) Positive for p-MAPK3/1 nuclear expression (white arrows). (**D**) Negative for p-MAPK3/1 expression (block arrow). Stromal cells serve as an internal positive control for p-MAPK3/1 expression (arrow).](6605846f2){#fig2}

![Kaplan--Meier curves for colorectal cancer-specific survival. (**A**) p-AMPK status and survival of colorectal cancer patients. The left panel includes all eligible cases, the middle panel includes p-MAPK3/1-positive cases, and the right panel includes p-MAPK3/1-negative cases. (**B**) p-MAPK3/1 status and survival of colorectal cancer patients. The left panel includes all eligible cases, the middle panel includes p-AMPK-positive cases, and the right panel includes p-AMPK-negative cases.](6605846f3){#fig3}

###### p-AMPK expression in colorectal cancer, and clinical, pathologic and molecular features

  **Clinical, pathologic**                                  **p-AMPK expression**              
  -------------------------------------------- ----------- ----------------------- ----------- ----------
  All cases                                        718               309               409      
  *Sex*                                           0.051                                        
   Male                                         259 (36%)         99 (32%)          160 (39%)   
   Female                                       459 (64%)         210 (68%)         249 (61%)   
                                                                                                
  *Age (years)*                                                                                
   ⩽59                                          143 (20%)         71 (23%)          72 (18%)   0.071
   60--69                                       301 (42%)         116 (38%)         185 (45%)   
   ⩾70                                          274 (38%)         122 (39%)         152 (37%)   
  *BMI*                                                                                        0.69
   \<30 kg m^--2^                               594 (83%)         254 (82%)         340 (83%)   
   ⩾30 kg m^--2^                                123 (17%)         55 (18%)          68 (17%)    
                                                                                                
  *Family history of colorectal cancer*           0.66                                         
   (−)                                          554 (77%)         236 (76%)         318 (78%)   
   (+)                                          164 (23%)         73 (24%)          91 (22%)    
                                                                                                
  *Tumour location*                               0.61                                         
   Proximal colon (cecum to transverse)         347 (49%)         155 (51%)         192 (48%)   
   Distal colon (splenic flexure to sigmoid)    220 (31%)         89 (29%)          131 (32%)   
   Rectum                                       140 (20%)         61 (20%)          79 (20%)    
                                                                                                
  *Stage*                                         0.16                                         
   I                                            160 (22%)         55 (18%)          105 (26%)   
   II                                           214 (30%)         100 (32%)         114 (28%)   
   III                                          204 (28%)         91 (29%)          113 (28%)   
   IV                                           101 (14%)         45 (15%)          56 (14%)    
   Unknown                                      39 (5.4%)         18 (5.8%)         21 (5.1%)   
                                                                                                
  *Tumour grade*                                 0.0009                                        
   Low                                          655 (92%)         269 (88%)         386 (95%)   
   High                                         60 (8.4%)         38 (12%)          22 (5.4%)   
                                                                                                
  *Tumour border*                                 0.80                                         
   Expansile                                    543 (86%)         237 (86%)         306 (85%)   
   Infiltrative                                 90 (14%)          38 (14%)          52 (15%)    
                                                                                                
  *p-MAPK3/1 expression*                                                                       
   (−)                                          469 (70%)         227 (80%)         242 (63%)  \<0.0001
   (+)                                          202 (30%)         57 (20%)          145 (37%)   
                                                                                                
  *TP53 expression*                               0.055                                        
   (−)                                          423 (59%)         194 (63%)         229 (56%)   
   (+)                                          290 (41%)         112 (37%)         178 (44%)   
                                                                                                
  *FASN expression*                               0.024                                        
   (−)                                          597 (84%)         267 (88%)         330 (81%)   
   (+)                                          114 (16%)         38 (12%)          76 (19%)    
                                                                                                
  *MSI*                                          0.0021                                        
   MSI-low/MSS                                  591 (84%)         242 (79%)         349 (88%)   
   MSI-high                                     113 (16%)         64 (21%)          49 (12%)    
                                                                                                
  *CIMP*                                                                                       
   CIMP-low/0                                   596 (85%)         237 (78%)         359 (89%)  \<0.0001
   CIMP-high                                    109 (15%)         66 (22%)          43 (11%)    
                                                                                                
  *LINE-1 methylation*                                                                         
   ⩾70%                                         121 (17%)         53 (18%)          68 (17%)   0.16
   50--69%                                      497 (71%)         220 (74%)         277 (70%)   
   \<50%                                        79 (11%)          26 (8.7%)         53 (13%)    
                                                                                                
  *BRAF mutation*                                 0.048                                        
   (−)                                          602 (85%)         250 (82%)         352 (88%)   
   (+)                                          104 (15%)          54(18%)          50 (12%)    
                                                                                                
  *KRAS mutation*                                 0.26                                         
   (−)                                          438 (62%)         195 (64%)         243 (60%)   
   (+)                                          271 (38%)         109 (36%)         162 (40%)   
                                                                                                
  *PIK3CA* mutation                                                                            0.79
   (−)                                          538 (84%)         236 (84%)         302 (83%)   
   (+)                                          106 (16%)         45 (16%)          61 (17%)    

Abbreviations: BMI=body mass index; CIMP=CpG island methylator phenotype; FASN=fatty acid synthase; MSI=microsatellite instability; MSS=microsatellite stable; p-AMPK=phosphorylated AMP-activated protein kinase; p-MAPK3/1=phosphorylated mitogen-activated protein kinase.

\% Number indicated the proportion of cases with a given clinical, pathologic or molecular feature among all cases, p-AMPK-negative cases or p-AMPK-positive cases.

###### p-AMPK status in colorectal cancer and patient mortality

                      **Colorectal cancer-specific mortality**  **Overall mortality**                                                      
  ------------ ----- ------------------------------------------ ----------------------- ------------------- ---------- ------------------- -------------------
  p-AMPK (−)    309                   86/2164                   1 (referent)            1 (referent)        125/2164   1 (referent)        1 (referent)
  p-AMPK (+)    409                   108/2952                  0.84 (0.61--1.17)       0.95 (0.71--1.28)   181/2952   1.08 (0.84--1.39)   1.12 (0.89--1.42)

Abbreviations: BMI=body mass index; CI=confidence interval; HR=hazard ratio; CIMP=CpG island methylator phenotype; FASN=fatty acid synthase; MSI=microsatellite instability; p-AMPK=phosphorylated AMP-activated protein kinase.

The multivariate, stage-matched (stratified) Cox model initially included sex, age at diagnosis, year of diagnosis, BMI, family history of colorectal cancer, tumour location, tumour grade, tumour border, CIMP, MSI, LINE-1 methylation, *BRAF*, *KRAS*, *PIK3CA*, TP53 and FASN. A backward stepwise elimination with a threshold of *P*=0.20 was used to select variables in the final model. Stage adjustment (I, IIA, IIB, IIIA, IIIB, IIIC, IV, unknown) was done using the 'strata\' option in the SAS 'proc phreg\' command.

###### p-AMPK status and patient mortality in strata of p-MAPK3/1 status (upper rows) and p-MAPK3/1 status and patient mortality in strata of p-AMPK status (lower rows)

                                             **Colorectal cancer-specific mortality**   **Overall mortality**                                                    
  ----------------------------------------- ------------------------------------------ ----------------------- ------------------- --------- ------------------- -------------------
  *p-MAPK3/1* (−)                                                                                                                                                          
   p-AMPK (−)                                                 59/227                        1 (referent)          1 (referent)      84/227      1 (referent)        1 (referent)
   p-AMPK (+)                                                 72/242                      1.14 (0.81--1.61)     1.22 (0.85--1.75)   106/242   1.20 (0.90--1.60)   1.31 (0.98--1.76)
                                                                                                                                                                           
  *p-MAPK3/1* (+)                                                                                                                                                          
   p-AMPK (−)                                                 23/57                         1 (referent)          1 (referent)       32/57      1 (referent)        1 (referent)
   p-AMPK (+)                                                 27/145                      0.39 (0.23--0.69)     0.42 (0.24--0.74)   62/145    0.64 (0.42--0.98)   0.65 (0.42--1.01)
                                                                                                                                                                           
  *p-AMPK* (−)                                                                                                                                                             
   p-MAPK3/1 (−)                                              59/227                        1 (referent)          1 (referent)      84/227      1 (referent)        1 (referent)
   p-MAPK3/1 (+)                                              23/57                       1.75 (1.08--2.82)     1.94 (1.17--3.24)    32/57    1.67 (1.12--2.50)   1.88 (1.23--2.86)
                                                                                                                                                                           
  *p-AMPK* (+)                                                                                                                                                             
   p-MAPK3/1 (−)                                              72/242                        1 (referent)          1 (referent)      106/242     1 (referent)        1 (referent)
   p-MAPK3/1 (+)                                              27/145                      0.55 (0.36--0.85)     0.55 (0.35--0.86)   62/145    0.84 (0.62--1.14)   0.80 (0.58--1.10)
  *P*~interaction~ (p-AMPK and p-MAPK3/1)                     0.0014                           0.0017                                0.016         0.0026                  

Abbreviations: BMI=body mass index; CI=confidence interval; HR=hazard ratio; p-AMPK=phosphorylated AMP-activated protein kinase; p-MAPK3/1=phosphorylated mitogen-activated protein kinase. The multivariate, stage-matched (stratified) Cox model included p-AMPK variable stratified by p-MAPK3/1 status (or p-MAPK3/1 variable stratified by p-AMPK status), sex, age, year of diagnosis, BMI, tumour location, tumour grade, tumour border, CIMP, MSI, LINE-1 methylation, *BRAF*, *KRAS*, *PIK3CA*, TP53 and FASN. A backward stepwise elimination with a threshold of *P*=0.20 was used to select variables in the final model. Stage adjustment (I, IIA, IIB, IIIA, IIIB, IIIC, IV, unknown) was done using the 'strata\' option in the SAS 'proc phreg\' command.

[^1]: These authors contributed equally to this work.
